Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomed Res Int ; 2022: 8620077, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35578721

RESUMO

Background: Palmitoylethanolamide is reported to solve pain and neuroinflammation in different models of chronic and neurodegenerative diseases. Some concerns have been illustrated for cautiously interpreting the available literature on the topic. Specifically, there is a lack of evidence about palmitoylethanolamide and female chronic pelvic pain. Concerns will be best solved by randomized trials. The present study was aimed at finding the best responders to micronized palmitoylethanolamide in female patient with chronic pelvic pain, using the existing literature at individual patient level, to help further randomized trial planning. Methods: After a systematic research, eligible studies (the ones enrolled female patients treated for chronic pelvic pain or for dyspareunia, dysuria, dyschezia, and dysmenorrhea with or without chronic pelvic pain) were assessed at individual patient data level. Conditional probabilities were calculated to assess variables conditioning the rates of good responders (pain score points more or equal to 3 reduction), poor responders (2 pain score reduction), and nonresponders at a three-month follow-up. Results: Only cases treated with palmitoylethanolamide comicronized with polydatin for a short period can be assessed. Good responders are more than 50%. In chronic pelvic pain, there is a 19.0% conditional probability to find good responders among patients with pain score at enrolment of 6 to 8 and of 6.8% to find poor responders among patients with a pain score at enrolment of 6 to 8. Painful disease does not matter on responders' rates. Conclusion: Best responders to comicronized palmitoylethanolamide/polydatin are patients with pain score higher than 6 at enrolment, irrespective of other variables.


Assuntos
Dor Crônica , Endometriose , Amidas , Dor Crônica/tratamento farmacológico , Dismenorreia , Etanolaminas/uso terapêutico , Feminino , Glucosídeos , Humanos , Ácidos Palmíticos/uso terapêutico , Dor Pélvica/tratamento farmacológico , Estilbenos
2.
Ann Endocrinol (Paris) ; 73(3): 230-2, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22503667

RESUMO

We report here a case of a paediatric hyperthyroidism due to a micro-macro-follicular thyroid adenoma in the presence of heterozygous point mutation of TSH receptor (TSHr). We describe the case from the initial diagnosis, through laboratoristic examinations and imaging techniques, until the radical surgical treatment made by a mini-cervicotomic videoassisted technique. We also explained the genetic work-up from peripheral blood and thyroid adenoma tissue.


Assuntos
Adenoma/cirurgia , Hipertireoidismo/etiologia , Receptores da Tireotropina/genética , Cirurgia Torácica Vídeoassistida/métodos , Neoplasias da Glândula Tireoide/cirurgia , Nódulo da Glândula Tireoide/congênito , Tireoidectomia/métodos , Adenoma/congênito , Adenoma/diagnóstico , Adenoma/tratamento farmacológico , Adenoma/genética , Adenoma/metabolismo , Substituição de Aminoácidos , Éxons/genética , Terapia de Reposição Hormonal , Humanos , Hiperplasia , Hipertireoidismo/congênito , Recém-Nascido , Masculino , Metimazol/uso terapêutico , Mutação de Sentido Incorreto , Neoplasias da Glândula Tireoide/congênito , Neoplasias da Glândula Tireoide/diagnóstico , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/genética , Neoplasias da Glândula Tireoide/metabolismo , Tiroxina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...